Fennec Pharmaceuticals (FENC) Tops Q3 EPS by 4c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $5.41 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Benchmark Starts Boyd Gaming (BYD) at Buy
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion